Background Severe iron overload due to recurrent transfusions for chronic anemia and inadequate iron chelation therapy in thalassemia major patients result in various complications, including hypothyroidism. Currently, there has been no data on the prevalence of hypothyroidism in thalassemia major patients at the Thalassemia Centers, Department of Child Health, Cipto Mangunkusumo Hospital (DCH CMH).
for thalassemia major patients, adherence to its use remains problematic. The clinical manifestations of hypothyroidism are nonspecific and patients are often unaware of their condition. Thus, early diagnosis of hypothyroidism could be more rapidly done through thyroid function tests. 8, [15] [16] [17] Despite the large numbers of new and returning patients in the Thalassemia Center, CMH, there has been no data collected on the prevalence of hypothyroidism in these patients. 18 In addition, there has been little research on primary hypothyroidism in the pediatric thalassemia major population in Indonesia. This study aims to determine the prevalence of thyroid dysfunction in thalassemia major patients using severe iron overload as one of the measures. It is hoped that this knowledge will help decrease morbidity and mortality of primary hypothyroidism as a treatment complication.
Methods
We conducted a cross-sectional, descriptive study at the Thalassemia Center, DCH CMH, Jakarta, from who underwent their last transfusion 2 weeks prior the study. The diagnosis of thalassemia major is established based on the need for regular transfusions, evidence of severe iron overload based on serum with acute infections, goiters, and those whose parents had a history of thyroid disorders. This study was approved by the Research Ethics Committee of the subjects' parents signed the informed consent.
Data regarding age, gender, type of thalassemia, disease duration, type of iron chelation therapy, adherence to chelation therapy, pre-transfusion Hb, and cumulative amount of transfused blood, were clinical symptoms of hypothyroidism, we obtained blood samples from the subjects and immediately TSH) and serum ferritin level measurement using electrochemiluminescence immunoassay decrease in thyroid hormone production due to dysfunction of the thyroid gland itself, while secondary and tertiary hypothyroidism occurs due to dysfunction of the pituitary and hypothalamus.
with elevated TSH levels and normal (compensated) Data was analyzed using the statistical package Subjects' characteristics were presented in percentages, means (standard deviation), and medians (range). The associations between variables and the incidence of hypothyroidism were analyzed using chi-square test or using Student's t-test or Mann-Whitney test, while the multivariate analysis was conducted using the considered statistically significant.
Results
During study period, 179 subjects with thalassemia major fulfilled the inclusion criteria. There was a and the remainder had HbE--thalassemia. The 31.8% of subjects were diagnosed before the age of 12 months. The average transfusion volume per year homozygous years, SD 2.8 years) for HbE--thalassemia. Other subject characteristics are shown in Table 1 .
chelation therapy, including most -thalassemia major -thalassemia who adhered to the iron chelation therapy was less than those who did not. DFX and the combination (26.8%), as stated in Table 2 . The youngest subject with homozygous -thalassemia who developed for HbE--thalassemia was 5 years old.
In comparing the means of the variables listed in Table 3 to thyroid status, there were significant differences in the hypothyroid group compared to the euthyroid group, for age, duration of illness, and cumulative amount of blood transfused. However, there were no significant differences between the the subjects' thyroid status and the mean transfusion the mean serum ferritin levels. There was also no significant difference in subjects' characteristic based on type of hypothyroidism. Table 4 shows significant risks for developing hypothyroidism based on age, duration of illness, and the cumulative volume of blood transfused. For subjects who had undergone regular iron chelation therapy, there was no significant risk difference for hypothyroidism between the subjects with disease duration of no significant hypothyroidism risk differences for the following variables: gender, pre-transfusion Hb levels, adherence to iron chelation therapy, and serum ferritin levels. The risk of hypothyroidism was also statistically insignificant when we compared the subjects with Further comparison of the hypothyroid C and D groups, revealed no statistically significant differences in the variables age, gender, duration of illness, cumulative blood volume transfused, adherence to iron chelation therapy, and serum ferritin levels. However, there was a significant risk difference in the and decompensated hypothyroidism. However, when we compared only subjects with hypothyroidism who used regular iron chelation therapy, there were no significant risk difference for the occurrence of compensated and decompensated hypothyroidism Bivariate analysis showed that three independent variables (age, duration of illness, and cumulative volume of blood transfused) contributed to statistically 
Discussion
Our study revealed a high percentage of hypooccurring at the age of quite high, compared with the results of other studies, The differences in prevalence may be caused by different protocols of therapy, namely the pre-transfusion Hb value used to warrant transfusion and patients' adherence to iron chelation therapy. In the Thalassemia Center, CMH, blood transfusion is carried out on patients studies, the pre-transfusion Hb levels were maintained is one cause of thyroid gland impairment. The euthyroid condition in the five subjects with mean significant risk differences between compensated and decompensated hypothyroidism with regards to mean pre-transfusion Hb, seem to support this hypothesis. In addition, the low adherence (33.5%) to iron chelation therapy also increased the risk of hypothyroidism.
Regular and adequate use of iron chelation has been shown to decrease the chance of hypothyroidism due to iron overload. This therapy was even shown to restore thyroid function in 52% of the subjects in a study by De Sanctis et al. 31 In other words, adequate iron chelation therapy and blood transfusions at ideal pre-transfusion Hb to justify transfusing should be implemented to decrease thyroid gland damage due function to its normal state.
Despite the high prevalence of hypothyroidism in this study, all subjects were clinically euthyroid, similar to previous study. 27 Complaints of lethargy and failure to thrive obtained from subjects with hypothyroidism could also be attributed to anemia as a part of thalassemia manifestation.
In this study, we found that subjects aged years, cumulative volume of transfused blood mL, and duration of illness of 8 years had statistically significant lower incidences of hypothyroidism. Similar to several other studies, we also did not find significant risk differences in hypothyroidism for the serum ferritin level variable. 11, 12 This observation may be due to the nature of serum ferritin level as an overall indicator of iron accumulation in the body. However, serum ferritin level in itself cannot give a complete picture of the body's actual condition, because its level can be influenced by other factors such as inflammatory processes, liver abnormalities, and malignancies. 32, 33 In addition, multifactorial etiologies from various endocrine abnormalities in thalassemia major, the difference of iron distribution in various organs, and the difference in sensitivity of various endocrine organs to iron cumulation are all possible reasons that we did not find associations between iron overload and thyroid dysfunction. 21 This study was conducted in the Thalassemia Center, CMH, one of the referral centers for thalassemia patients in Jakarta and the surrounding Therefore, the subjects included in this study were assumed to represent the population of pediatric thalassemia patients in Indonesia. This study also included two types of thalassemia major most commonly found in Indonesia, homozygous -thalassemia and HbE--thalassemia. To lower the thalassemia patients with other conditions that could cause thyroid function impairment, such as goiter of thyroid disorder.
One of the limitations of this study was that the measurement of variables was only conducted once, was the consecutive sampling method that we used. In addition, the data on adherence to regular bias. The data on the cumulative volume of blood received by the subjects since they were first diagnosed was taken entirely from secondary data in the subjects' medical records in CMH. However, because CMH is a teaching hospital, the quality of its medical records is fairly reliable. The measurement for severity of iron accumulation entirely relied on the results of serum ferritin levels as up to this point, it was the most practical test available in Indonesia to measure the severity of iron accumulation in the body.
The fairly high prevalence of hypothyroidism in this study suggests the importance of regular thyroid function monitoring for pediatric thalassemia major patients, in order to detect and implement early treatment. Moreover, with the finding of subjects is important to develop new recommendations for initiation of thyroid function screening on younger aged children in the Thalassemia Center, DCH CMH. Based on the analysis using ROC curves, the age 8.5 years can be recommended as the age to initiate thyroid function test in patients with thalassemia major. However, the clinical condition of thalassemia major patients aged 8.5 years may vary in terms of duration of illness, due to the differences in ages of diagnosis and according to the type of thalassemia. Consequently, for clinical application purposes, it may be better to use the cutoff point of 6.3 years duration of as the recommended time to initiate thyroid function tests on thalassemia major subjects. Using the cutoff point of cumulative volume of transfused blood is not recommended as a guide for initiating thyroid application.
In conclusion, the prevalence of primary hypothyroidism in our study was high, higher than that of other studies. The high prevalence of hypothyroidism and the finding that many subjects toward the importance of conducting thyroid function screenings earlier in life compared to the currently used procedures. We recommend starting thyroid function evaluations on thalassemia major patients hundred patients with beta-thalassemia major. Thyroid. 
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